Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOSTER evolving study platform with CabOS randomization in osteosarcoma
NL-OMON61352Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabozantinib in osteosarcoma (OS), sponsored by Gustave Roussy. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NL-OMON61352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61352.